N-(4-chloro-2-pyrimidinyl)-N,2,3-trimethyl-2H-Indazol-6-amine | 1252927-45-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4-chloro-2-pyrimidinyl)-N,2,3-trimethyl-2H-Indazol-6-amine
• 英文别名: N-(4-chloropyrimidin-2-yl)-N,2,3-trimethylindazol-6-amine
• CAS: 1252927-45-9
• 化学式: C₁₄H₁₄ClN₅
• 分子量: 287.75
• InChiKey: JYPPKOMRVIEEAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  46.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• AN IMPROVED PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Laurus Labs Private Limited

  公开号：US20160280689A1

  公开（公告）日：2016-09-29

  The present invention is relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof.

  本发明涉及一种改进的帕唑帕尼布或其药用可接受盐的制备方法。本发明还涉及帕唑帕尼布盐酸盐的新型多形态形式及其中间体。
• Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
  申请人：Laurus Labs Private Limited

  公开号：US10730859B2

  公开（公告）日：2020-08-04

  The present invention is relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof.

  本发明涉及一种用于制备帕唑帕尼或其药学上可接受的盐类的改进工艺。本发明还涉及盐酸帕唑帕尼的新型多晶型及其中间体。
• Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof
  申请人：Laurus Labs Limited

  公开号：US11299477B2

  公开（公告）日：2022-04-12

  The present invention is relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof.

  本发明涉及一种用于制备帕唑帕尼或其药学上可接受的盐类的改进工艺。本发明还涉及盐酸帕唑帕尼的新型多晶型及其中间体。
• PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Laurus Labs Limited

  公开号：US20200262821A1

  公开（公告）日：2020-08-20

  The present invention is relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof,